 |
|
|
| 1910 |
|
Instituto Central de Análisis Clínicos |
|
|
|
| 1943 |
|
Medicine for transfusion: lyophilized plasma from a single donor |
|
|
|
| 1951 |
|
Development of plasmapheresis. Blood bank activities and manufacture of IV solutions
commence.
|
|
|
|
| 1957 |
|
Gri-Cel: manufacture of medical instruments. |
|
|
|
| 1966 |
|
Cell-Washer centrifuge. |
|
|
|
| 1972 |
|
The new production facilities move from Barcelona to Parets del Vallès.
Industrial plasma fractionation. Beginning of cryoprecipitate production.
|
|
|
|
| 1980 |
|
Marketing of FVIII concentrate |
|
|
|
| 1984 |
|
Production of virally inactivated FVIII concentrate. |
|
|
|
| 1986 |
|
Prothrombin Concentrate Complex |
|
|
|
| 1991 |
|
Foundation of Biomat. |
|
|
|
| 1992 |
|
Marketing of lyophilized IVIG. |
|
|
|
| 1994 |
|
Marketing of Pasteurized Liquid IVIG and Fanhdi® double inactivated FVII/VWF High
Purity.
|
|
|
|
| 1994 |
|
Marketing of blood bags. |
|
|
|
| 1995 |
|
Launching of Diana® System. |
|
|
|
| 1995 |
|
Obtaining the Establishment License and the product license for albumin granted by the
American Food & Drug Administration (FDA).
|
|
|
|
| 1997 |
|
Viral Inactivation Service of Transfusional Plasma (MB-VIP) |
|
|
|
| 1998 |
|
Launching of WADiana® |
|
|
|
| 1999 |
|
Launching of Triturus® and Soyacal® |
|
|
|
| 2000 |
|
Marketing of Leucored® (Blood Bags with Online filter) |
|
|
|
| 2004 |
|
Launch of high purity double inactivated factor IX concentrate.
Launch of DG Gel® and Grifill® 3.0
ISO 14001 certification obtained. |
|
|
|
| 2005 |
|
Anbinex®, antithrombin III concentrate, marketed.
Launch of Grifols Partnership, a manufacturing service for sterile solutions to third parties.
Fleboflex®, polypropylene bags for intravenous solutions.
Tauramin marketed, amino acid solution for clinical nutrition. |
|
|
|
| 2006 |
|
FDA licence obtained for Flebogamma® DIF IGIV and for the new IGIV manufacturing plant in Barcelona. |
|
|
|
| 2007 |
|
FDA approval of Alphanate® to treat VWD.
EMEA grants license for Flebogammadif®.
Launch of the new hemostasis autoanalyzer. |
|
|
|
| 2008 |
|
Obtained the new FDA license for the new coagulation factor sterile dosage activity in the plasma derivatives plant in Los Angeles.
Grifols began marketing its PediGri® On Line information system in the US. This product allows healthcare professionals to accurately trace the plasma used in all of Grifols’ plasma derivatives, from the time of donation to the manufacture of the end product.
Grifols obtains licensing for its intravenous immunoglobulin, Flebogamma® 5% DIF, in Australia.
|
|
|
|
Timeline
